SIMES STEPHEN M 4

What Happened Stephen M. Simes, a director of CytoDyn Inc. (CYDY), received a grant of 574,385 derivative securities reported on March 20, 2026. The filing lists a $0.00 acquisition price (no cash consideration reported). The grant was approved by the company’s Compensation Committee as the annual award for fiscal 2026 and was made from shares reserved under the Issuer’s 2012 Equity Incentive Plan.

Key Details

• Transaction date: 2026-03-20; Form 4 filed: 2026-03-24 (timely within the SEC’s two-business-day requirement).
• Amount granted: 574,385 derivative securities (reported as an award/grant, code A).
• Price reported: $0.00 (no cash paid at grant).
• Vesting: the award (described as a stock option in the footnote) vests in approximately 12 equal monthly installments from April 2026 through March 2027.
• Source: Approved by the Compensation Committee and issued from shares reserved under the 2012 Equity Incentive Plan.
• Shares owned after the transaction: not specified in the filing.

Context This is a compensation grant to a director (an annual award consistent with prior practice), not an open-market purchase or sale. Because it’s a derivative award that vests over time, it does not represent immediately tradable shares; future ownership and any realized value will depend on vesting and any exercise terms. The filing does not disclose an immediate sale or cashless exercise.